Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.

The main purpose of the test: to study the single oral administration of the test preparation Pregabalin Capsules (specification: 150 mg, produced by Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd.) and the reference preparation Pregabalin Capsules (Lerrica) in fasting and postprandial states. ®, strength: 150 mg; manufactured by Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg) in healthy participants to evaluate the bioequivalence of the two oral formulations in the fasting and postprandial states. Secondary trial purpose: To study the safety of the test preparation Pregabalin Capsules (specification: 150 mg) and the reference preparation Pregabalin Capsules (Lerica®) (Specification: 150 mg) in healthy participants.

Main research purpose: To study the single administration of the test preparation levetiracetam sustained-release tablets (specification: 0.5 g, produced by Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd.) and the reference preparation levetiracetam under fasting and postprandial conditions Pharmacokinetics of racetam extended-release tablets (KEPPRA Secondary study objectives: To evaluate the efficacy of test formulation levetiracetam extended-release tablets (strength: 0.5 g) and reference formulation levetiracetam extended-release tablets (KEPPRA XR®, strength: 500 mg) in healthy subjects security in.

Primary study objective To evaluate the absorption rate and extent of dapoxetine hydrochloride tablets and Priligy® in healthy male subjects after meals, and to evaluate whether the two preparations are bioequivalent. Secondary study objective To evaluate the safety of the test preparation dapoxetine hydrochloride tablets and the reference preparation Priligy® in healthy male subjects.